Menu
/REGISTER
Montecito
Pac Premier
Loading...
You are here:  Home  >  'Kyprolis'  -  Page 2
Latest

Drug sales for biotech giant Amgen boost bottom line

By   /  Friday, February 10th, 2017  /  Central Coast Health Watch, Earnings, left, Technology, Tri-County Public Companies  /  Comments Off on Drug sales for biotech giant Amgen boost bottom line

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen beats analysts’ revenue, earnings per share estimates

By   /  Thursday, October 27th, 2016  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies  /  Comments Off on Amgen beats analysts’ revenue, earnings per share estimates

Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →

Read More →
Latest

Amgen leukemia drug cures 39 percent of treated patients, study finds

By   /  Tuesday, October 4th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen leukemia drug cures 39 percent of treated patients, study finds

Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →

Read More →
Latest

Amgen reports revenue increase in second quarter earnings

By   /  Wednesday, July 27th, 2016  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies, West Ventura County  /  Comments Off on Amgen reports revenue increase in second quarter earnings

Updated on July 27 at 4 p.m.: Amgen reported a 6 percent increase in revenue and a 15 percent increase in earnings per share in its second quarter earnings released July 27. Revenues grew to $5.7 billion due to higher sales of the company’s drugs Enbrel, Prolia, Kyprolis and Xgeva, and operating income increased 15 Read More →

Read More →
Latest

Europeans OK Amgen’s Kyprolis for multiple myeloma treatment

By   /  Tuesday, July 5th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Europeans OK Amgen’s Kyprolis for multiple myeloma treatment

European regulators approved Amgen’s potential blockbuster drug Kyprolis on July 4 as a treatment for multiple myeloma. The European Commission approved a treatment of Kyprolis and dexamethasone in patients who’ve received at least one previous multiple myeloma treatment. In November, the commission approved a Kyprolis treatment using lenalidomide and dexamethasone for patients who’ve received at Read More →

Read More →
Latest

Amgen exceeds Wall Street expectations for first quarter earnings

By   /  Thursday, April 28th, 2016  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies  /  Comments Off on Amgen exceeds Wall Street expectations for first quarter earnings

Amgen blew away Wall Street expectations and raised its 2016 guidance when it released first quarter earnings April 28. The Thousand Oaks biotech giant had profits of $2.2 billion, up from $1.91 billion during the same quarter last year. Revenues of $5.53 billion were also up from $5 billion in 2015 and surpassed analyst estimates Read More →

Read More →
Latest

Amgen drug Kyprolis gets another FDA approval

By   /  Thursday, January 21st, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on Amgen drug Kyprolis gets another FDA approval

Amgen scored another victory for its breakthrough multiple myeloma drug on Jan. 21. The Thousand Oaks-based biotech giant hit it big when the Food and Drug Administration approved revolutionary multiple myeloma drug Kyprolis for treatments with Kyprolis in combination with another drug. The FDA also approved Kyprolis to treat patients on its own for those Read More →

Read More →